Eris Lifesciences
Pure-play India branded company concentrated in chronic cardio-metabolic therapies; aggressively building derma, nephrology and injectables via acquisitions (Biocon-derma, Swiss Parenterals, Bharat Serums-linked).
A full research profile for one company — what it does, how its financials have trended, how the market values it, and a balanced bull/bear/base investment memo.
Scan the top row for the headline numbers, read the charts for trends, check the three gauge scores, then read the auto-generated memo at the bottom. Sources for every figure are linked at the very bottom.
- EBITDA
- — Earnings before interest, tax, depreciation & amortisation — a proxy for operating cash profit.
- PAT
- — Profit After Tax — the bottom-line net profit.
- FCF
- — Free Cash Flow — cash left after running the business and capital spending.
- ANDA
- — Abbreviated New Drug Application — the US FDA filing to sell a generic drug.
Revenue
₹ crore · FY
EBITDA
₹ crore · FY
Margins
EBITDA & PAT margin %
R&D Spend
₹ crore · FY
Free Cash Flow
₹ crore · FY
Revenue Mix
By geography / segment
Quality Score
Growth Score
Regulatory Risk
Snapshot
Business Model
How the company makes money
Pure-play India chronic branded generics (cardio-metabolic, derma, injectables via acquisitions).
Chronic + injectables/derma acquisitions
Acquisition leverage (D/E ~0.9) & NLEM exposure
Peer Group
Click to compare
| Peer | Rev CAGR | EBITDA% | ROCE | P/E |
|---|---|---|---|---|
| Eris Lifesciences | 14% | 35% | 14% | 31x |
| J.B. Chemicals & Pharmaceuticals | 23% | 26% | 26% | 49x |
| Ajanta Pharma | 19% | 27% | 32.3% | 36x |
| Mankind Pharma | 0% | 25% | 13.5% | 49x |
| Torrent Pharmaceuticals | 25% | 32% | 27% | 68x |
Investment Memo
Auto-generated from the data layer — illustrative, not advice
- • Chronic + injectables/derma acquisitions underpins a 14% 5Y revenue CAGR.
- • Premium 35% EBITDA margin with 14% ROCE signals durable economics.
- • Capacity already in place to support the next growth phase.
- • Acquisition leverage (D/E ~0.9) & NLEM exposure.
- • Pricing/NLEM exposure on the domestic book can cap realisation.
- • Re-rating depends on proving R&D/return discipline.
Eris Lifesciences screens as a improving domestic formulations franchise. With revenue of ₹2.9K Cr growing ~14% and 35% EBITDA margins, the base case is steady compounding driven by chronic + injectables/derma acquisitions, while watching acquisition leverage (d/e ~0.9) & nlem exposure.
Trades at 31x P/E, 19.0x EV/EBITDA and 5.0x P/B. Reasonable versus growth — re-rating optionality if execution improves.
- 1 India IPM outperformance & chronic mix
- 2 Gross-margin trajectory & new-launch contribution
- 3 R&D productivity (filings/approvals per ₹ of R&D)
- 4 Capital allocation — capex payback & M&A discipline
FY25 PAT margin ~12% (down YoY on acquisition costs/interest); D/E ~0.9 from M&A. Listed 2017 → 10Y n/a. Essentially India-only.